EXELIXIS, INC. (EXEL)
About EXELIXIS, INC.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.
Financial summary
- Revenue FY2026
- $2.3B
- Net income
- $782.6M
- Total assets
- $2.8B
- Market cap
- $13.9B
Source: SEC EDGAR · updated Jun 7, 2026
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $13.9B
- Shares outstanding
- 213.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 11, 2000
Exelixis, Inc. (EXEL) Stock Price
- Profitable — net income of $782.6M in FY2026.
- Trading near its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review EXELIXIS, INC..
Write a review
News about EXELIXIS, INC.
News & sentiment via Polygon.io
Exelixis, Inc.: frequently asked questions
Is Exelixis, Inc. an American company?
Yes — Exelixis, Inc. is an American company headquartered in Alameda, California. Its American-origin credentials have been independently reviewed and verified by americancompanies.com.
Where is Exelixis, Inc. headquartered?
Exelixis, Inc. is headquartered in Alameda, California, United States.
Is Exelixis, Inc. publicly traded?
Yes — Exelixis, Inc. is a publicly traded company. Its stock trades under the ticker symbol EXEL on the NASDAQ.
What does Exelixis, Inc. do?
Exelixis, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
